CCCC’s protein-degrader bet: small-cap biotech swinging for big wins

The thesis

C4 Therapeutics (CCCC) is a small biotech trying to turn its protein‑degrading science into real cancer drugs, with enough cash and partners to buy time. Its lead drug, cemsidomide, is in a Phase 2 trial called MOMENTUM for multiple myeloma, aiming to enroll about 100 patients and finish around early 2027.[4] C4 just reported Q1 2026 results: loss of $25.1M, but with $268.3M in cash and investments, which management says should fund them through at least the end of 2028.[2][4] On the business side, they deepened a long‑term partnership with Roche in April 2026, adding a degrader‑antibody deal that brought in a $20M upfront payment plus over $1B in potential future milestones if things go well.[2][4] Near‑term stock moves will likely hinge on cemsidomide data at medical conferences and steady progress updates from the Roche and Biogen programs.[4][5]

Everyone wishes they'd bought Nvidia early. Here's how to spot the next one.

The biggest winners of the last decade had one thing in common. Our data follows those exact moves — and turns them into 10 names to watch right now.

The big names in the AI, Space, Nuclear and Robotics race. The window to get in early is closing fast. Don't wait.

See the top 10 stocks now — free ›

💡 Why this matters

C4 sits at the intersection of two big health trends: using genetics to understand disease and designing smarter drugs that destroy harmful proteins instead of just blocking them. That’s a fancy way of saying they’re trying to “tag” bad proteins so the body’s own trash‑disposal system throws them out. If this works, it could lead to longer‑lasting cancer treatments, possibly with fewer side effects than older chemo‑style drugs.[4][5] For regular investors, this is a classic higher‑risk, higher‑reward biotech: one or two clear clinical wins or a big‑pharma deal can reprice the stock quickly, but setbacks can hit hard.[2][4]

▲ Catalysts

+ Q2 2026 earnings call expected in early August 2026; any cash runway update or partnership news can move the stock.[1][7]
+ Ongoing Phase 2 MOMENTUM trial of cemsidomide in multiple myeloma, targeting ~100 patients with completion around Q1 2027; interim updates matter.[4]
+ New April 2026 Roche degrader‑antibody partnership: $20M upfront and $1B+ in potential milestones; early progress readouts would be a positive signal.[2][4]
+ Biogen BTK degrader program earned C4 a $2M milestone in January 2026; further milestones as Biogen advances trials would validate the platform.[5]
+ Planned additional Phase 1b cemsidomide combo trial with existing myeloma drugs in first half 2027; trial launch and early safety data are watch points.[4]

▼ Risks

! This is still a money‑losing biotech: Q1 2026 net loss was $25.1M, and future trials will keep burning cash.[2][4]
! Past equity raise in October 2025 brought in $125M and warrants; more stock sales later could dilute existing shareholders.[5]
! Drug development risk: cemsidomide or partner drugs could show weak results or safety issues, which would heavily hit the stock.[4][5]
! All revenue today comes from partners, not approved drugs; if Roche or Biogen slow or cancel programs, that support could shrink.[2][4][5]

🎯 One thing to take away

C4 Therapeutics is an early‑stage cancer‑drug company trying to use the body’s own garbage‑disposal system to get rid of bad proteins in cancer cells. Right now, it has no approved drugs, just trials – the main one is a mid‑stage study in blood cancer (multiple myeloma) that runs into 2027.[4] The good news: they had about $268M in cash at the end of March 2026, which they say should last through 2028, and they just expanded a big partnership with Roche that brought in $20M upfront plus a shot at over $1B in milestones.[2][4] The flip side: they’re still losing around $25M a quarter, and any weak trial result or slow partner progress could punish the stock. This is one to study if you’re comfortable with small‑cap biotech swings and are looking for a platform‑style cancer story rather than near‑term profits.

📊 CCCC fundamentals

Revenue, net income, EPS & balance sheet — straight from SEC filings.

View →

Data sources & methodology

All figures derive from official, public-domain government filings. Read our methodology for how we collect, process and score this data. See the methodology →

TZ Researched & published by TradesZ Research

Want our premium picks too?

Pro subscribers get our strongest pre-pop ideas + real-time buy-zone alerts.

Thinking about CCCC?

Our data likes 10 other stocks even more right now — under-the-radar names we believe have monster upside potential. Get the free list before the crowd catches on.

Show me the 10 stocks — free →

Free · no credit card · unsubscribe in one click

Not investment advice. We share research and analyses for educational purposes. Investing in stocks involves risk, including possible loss of capital. Always do your own research.